Literature DB >> 21600016

Marked increase in etravirine and saquinavir plasma concentrations during atovaquone/proguanil prophylaxis.

Chiara Tommasi1, Rita Bellagamba, Massimo Tempestilli, Antonio D'Avolio, Anna L Gallo, Jelena Ivanovic, Emanuele Nicastri, Leopoldo P Pucillo, Pasquale Narciso.   

Abstract

The case of a 32-year-old Caucasian female with multi-drug resistant HIV-1 subtype B infection treated with a salvage regimen including maraviroc, raltegravir, etravirine and unboosted saquinavir who started atovaquone/proguanil prophylaxis, is reported. The potential interactions between atovaquone/proguanil and these anti-retroviral drugs are investigated. Pharmacokinetic analyses documented a marked increase in etravirine and saquinavir plasma concentrations (+55% and +274%, respectively), but not in raltegravir and maraviroc plasma concentrations. The evidence that atovaquone/proguanil significantly interacts with etravirine and saquinavir, but not with raltegravir and maraviroc, suggests that the mechanism of interaction is related to cytochrome P450.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21600016      PMCID： PMC3112458          DOI： 10.1186/1475-2875-10-141

Source DB:  PubMed          Journal:  Malar J        ISSN： 1475-2875            Impact factor:   2.979


  11 in total

1.  A rare case of severe myopathy associated with etravirine use.

Authors:  Chiara Tommasi; Massimo Tempestilli; Rita Fezza; Rita Bellagamba; Emanuele Nicastri; Gianpiero D'offizi; Leopoldo P Pucillo; Pasquale Narciso
Journal:  AIDS       Date:  2010-04-24       Impact factor: 4.177

Review 2.  Maraviroc: pharmacokinetics and drug interactions.

Authors:  Samantha Abel; David J Back; Manoli Vourvahis
Journal:  Antivir Ther       Date:  2009

3.  Lower atovaquone/proguanil concentrations in patients taking efavirenz, lopinavir/ritonavir or atazanavir/ritonavir.

Authors:  Matthijs van Luin; Marchina E Van der Ende; Clemens Richter; Mirjam Visser; Diari Faraj; Andre Van der Ven; Luc Gelinck; Frank Kroon; Ferdinand W Wit; Ron H N Van Schaik; Paul F M Kuks; David M Burger
Journal:  AIDS       Date:  2010-05-15       Impact factor: 4.177

4.  HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter.

Authors:  C G Lee; M M Gottesman; C O Cardarelli; M Ramachandra; K T Jeang; S V Ambudkar; I Pastan; S Dey
Journal:  Biochemistry       Date:  1998-03-17       Impact factor: 3.162

5.  Atovaquone-proguanil: report from the CDC expert meeting on malaria chemoprophylaxis (II).

Authors:  Andrea K Boggild; Monica E Parise; Linda S Lewis; Kevin C Kain
Journal:  Am J Trop Med Hyg       Date:  2007-02       Impact factor: 2.345

6.  Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.

Authors:  M Iwamoto; L A Wenning; A S Petry; M Laethem; M De Smet; J T Kost; S A Merschman; K M Strohmaier; S Ramael; K C Lasseter; J A Stone; K M Gottesdiener; J A Wagner
Journal:  Clin Pharmacol Ther       Date:  2007-08-22       Impact factor: 6.875

7.  Human immunodeficiency virus protease inhibitors serve as substrates for multidrug transporter proteins MDR1 and MRP1 but retain antiviral efficacy in cell lines expressing these transporters.

Authors:  R V Srinivas; D Middlemas; P Flynn; A Fridland
Journal:  Antimicrob Agents Chemother       Date:  1998-12       Impact factor: 5.191

Review 8.  Maraviroc, a chemokine CCR5 receptor antagonist for the treatment of HIV infection and AIDS.

Authors:  Nicholas A Meanwell; John F Kadow
Journal:  Curr Opin Investig Drugs       Date:  2007-08

9.  A validated high-performance liquid chromatography-ultraviolet method for quantification of the CCR5 inhibitor maraviroc in plasma of HIV-infected patients.

Authors:  Antonio D'Avolio; Marco Simiele; Lorena Baietto; Marco Siccardi; Mauro Sciandra; Samantha Patanella; Stefano Bonora; Giovanni Di Perri
Journal:  Ther Drug Monit       Date:  2010-02       Impact factor: 3.681

Review 10.  Clinical pharmacokinetics and pharmacodynamics of etravirine.

Authors:  Monika Schöller-Gyüre; Thomas N Kakuda; Araz Raoof; Goedele De Smedt; Richard M W Hoetelmans
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447
View more
  4 in total

Review 1.  Antimalarial pharmacology and therapeutics of atovaquone.

Authors:  Gemma L Nixon; Darren M Moss; Alison E Shone; David G Lalloo; Nicholas Fisher; Paul M O'Neill; Stephen A Ward; Giancarlo A Biagini
Journal:  J Antimicrob Chemother       Date:  2013-01-04       Impact factor: 5.790

2.  Inhibition of Plasmodium Hepatic Infection by Antiretroviral Compounds.

Authors:  Marta Machado; Margarida Sanches-Vaz; João P Cruz; António M Mendes; Miguel Prudêncio
Journal:  Front Cell Infect Microbiol       Date:  2017-07-19       Impact factor: 5.293

3.  Development of an evidence evaluation and synthesis system for drug-drug interactions, and its application to a systematic review of HIV and malaria co-infection.

Authors:  Kay Seden; Sara Gibbons; Catia Marzolini; Jonathan M Schapiro; David M Burger; David J Back; Saye H Khoo
Journal:  PLoS One       Date:  2017-03-23       Impact factor: 3.240

4.  Atovaquone and quinine anti-malarials inhibit ATP binding cassette transporter activity.

Authors:  Sanna R Rijpma; Jeroen J M W van den Heuvel; Maarten van der Velden; Robert W Sauerwein; Frans G M Russel; Jan B Koenderink
Journal:  Malar J       Date:  2014-09-13       Impact factor: 2.979
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.